Literature DB >> 9195551

Antioxidant function of ambroxol in mononuclear and polymorphonuclear cells in vitro.

A Gillissen1, A Bartling, S Schoen, G Schultze-Werninghaus.   

Abstract

This study quantifies the antioxidant function of ambroxol (2-amino-3,5-dibromo-N-[trans-4-hydroxycyclohexyl]benzylamine) in vitro. Polymorphonuclear cells (PMN) and mononuclear cells were isolated from the blood of healthy volunteers (n = 46) to determine reactive oxygen species (ROS) by luminol-enhanced chemiluminescence. Ambroxol or the controls N-acetylcysteine (NAC), nacystelyn (NAL), glutathione (GSH), superoxide dismutase (SOD), catalase, and the combination of SOD/catalase were incubated for 1 or 2 h with zymosan-activated cells in vitro using concentrations ranging from 10(-6) to 10(-3) mol/liter. Reduction of ROS-mediated luminescence was similar within the cell types. Ambroxol (10(-4) mol/liter) reduced ROS about 75% (1-h incubation) and 98% (2-h incubation), respectively (p < 0.001). SOD and SOD/catalase, but not the H2O2-catalyzing substances (NAC, NAL, GSH, and catalase), reduced cellular ROS. This indicates that inflammatory cells predominantly generate O2-, which can be scavenged by ambroxol. The antioxidant function of ambroxol with increasing incubation time suggests additional cellular antiinflammatory properties of this substance. Our results indicate that good antioxidant function of ambroxol is related mainly to direct scavenger function of reactive oxygen metabolites such as O2-. However, an antioxidative effect of ambroxol may also be associated with the reduction of prooxidative metabolism in inflammatory cells. Concluding from this observation, and because of the well known high affinity of ambroxol for lung tissue, ambroxol may be an alternative in antioxidant augmentation therapy, particularly in pulmonary diseases characterized by an overburden of toxic oxygen metabolites.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9195551     DOI: 10.1007/pl00007570

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  9 in total

Review 1.  [Good sense and nonsense of antitussive agents].

Authors:  A Gillissen; S Tasci; S Ewig; H Schäfer; S Zielen
Journal:  Internist (Berl)       Date:  2001-01       Impact factor: 0.743

Review 2.  Ambroxol: a CNS drug?

Authors:  Thomas Weiser
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

3.  In vitro inhibition of human neutrophil histotoxicity by ambroxol: evidence for a multistep mechanism.

Authors:  Luciano Ottonello; Nicoletta Arduino; Maria Bertolotto; Patrizia Dapino; Marina Mancini; Franco Dallegri
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

4.  Anti-inflammatory effects of Myrtol standardized and other essential oils on alveolar macrophages from patients with chronic obstructive pulmonary disease.

Authors:  U Rantzsch; G Vacca; R Dück; A Gillissen
Journal:  Eur J Med Res       Date:  2009-12-07       Impact factor: 2.175

5.  A simple cost-effective modification improves the quality of immunocytochemical staining in cervical scrape samples characterized by presence of excess mucus.

Authors:  Sagar Pawar; Umesh Mahantshetty; Kedar Deodhar; Tanuja Teni
Journal:  J Histotechnol       Date:  2014-03       Impact factor: 0.714

Review 6.  Antioxidant therapy as a potential approach to severe influenza-associated complications.

Authors:  Noboru Uchide; Hiroo Toyoda
Journal:  Molecules       Date:  2011-02-28       Impact factor: 4.411

7.  Immunomodulatory Effects of Ambroxol on Airway Hyperresponsiveness and Inflammation.

Authors:  Katsuyuki Takeda; Nobuaki Miyahara; Shigeki Matsubara; Christian Taube; Kenichi Kitamura; Astushi Hirano; Mitsune Tanimoto; Erwin W Gelfand
Journal:  Immune Netw       Date:  2016-06-17       Impact factor: 6.303

8.  Ambroxol for the treatment of fibromyalgia: science or fiction?

Authors:  Kai-Uwe Kern; Myriam Schwickert
Journal:  J Pain Res       Date:  2017-08-16       Impact factor: 3.133

9.  Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide.

Authors:  Xiao Su; Ling Wang; Yuanlin Song; Chunxue Bai
Journal:  Intensive Care Med       Date:  2003-09-20       Impact factor: 17.440

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.